

## Hepatology COVID-19 Registry

## Week 9 Report

2 new cases added to the report since last week

	Chronic liver disease (N=19)	Post-liver transplantation (N=18)
<b>Gender (%)</b>	Female = 10 (52.6%) Male = 9 (47.4%)	Female = 8 (44.4%) Male = 10 (55.6%)
<b>Median Age (yr) at time of COVID diagnosis (range)</b>	6.5 (0.16-20)	10.5 (0.5-21)
<b>Etiology of liver disease</b>	Biliary atresia = 6 NAFLD = 5 Autoimmune hepatitis = 3 Metabolic disorder = 1 Others* = 4	Biliary atresia = 8 Acute liver failure = 5 Metabolic disorders = 1 Tumor = 2 Others** = 2
<b>Highest level of care</b>		
Outpatient	5	12
Hospital floor	9	3
ICU	5	3
<b>Immunosuppression at time of COVID diagnosis</b> (*some patients were on multiple agents)	Azathioprine = 3 Steroids = 1 No Immunosuppression = 16	Tacrolimus = 14 Steroids = 7 Mycophenolate Mofetil = 6 Sirolimus = 2 Cyclosporine = 1
<b>Specific Treatment for COVID</b> (*some patients were on multiple agents)	Hydroxychloroquine + Azithromycin = 3 IVIG = 3 Steroids = 3 Tocilizumab + Sarilumab = 1 Rocilizumab Sarilumab = 1 Remdesivir = 2 Convalescent Plasma = 1 Anticoagulation = 1 Anakinra = 1 Eculizimab = 1	Azithromycin = 1 Hydroxychloroquine = 2 IVIG = 1 Favipiravir = 1
<b>Highest respiratory support</b>		
None	13	16
Nasal cannula/CPAP/BiPAP	3	2
Mechanical ventilation	2	0
High Frequency Oscillatory ventilation	1	0
Pending information	-	-
<b>Final clinical outcome</b>		
Death	1***	0
Recovery	16	15
Still active in clinical course	2	3
Pending information	-	-
<b>Liver related Complications</b>	Ascites = 5 Portal Hypertension Bleeding = 1	-


\*Others CLD: idiopathic cholestasis, GVHD/vanishing bile duct syndrome (Post BMT), IFALD with biliary obstruction, PFIC

\*\* Others PLT: IFALD

\*\*\*Due to non Hepatic causes


Two recipients had multivisceral transplantation

### Presenting symptoms at time of diagnosis



\*Constitutional symptoms reported: Loss of smell/taste , fever, myalgia, fatigue, sore throat  
# Other symptoms reported: Malaise, anorexia, headache, rash, Kawasaki disease like presentation (MIS-C)

### Change done to Immunosuppressive agent (Post LT)



\*Stopped, decreased the dose, others and No changes  
Commonest agent **stopped**: Mycophenolate Mofetil